BioInformant

Your Global Leader in Stem Cell Market Research

MENUMENU
  • Blog
  • Stem Cells
    • iPS Cells
    • MSCs
    • HSCs
    • Adipose SCs
    • Neural Stem Cells
  • Cell Therapy
    • COVID-19
    • CAR-T
    • Cord Blood
  • Exosomes
  • Interviews
  • News
    • Press Releases
    • Job Posts
  • Shop
    • Products
    • Submit PR
    • Advertise
  • About
    • Testimonials
    • Story
    • Guarantee
    • Contact
  • Home
  • Blog
    • Stem Cells
      • HSCs
      • iPS Cells
      • MSCs
      • Neural Stem Cells
      • Adipose SCs
    • Exosomes
    • Cell Therapy
      • CAR-T
    • Cord Blood
    • Stem Cell News
    • Interviews
  • COVID-19
  • Shop
  • Submit PR
  • Company
    • Advertise
    • Testimonials
    • Story
    • Job Posts
    • Guarantee
    • Privacy Policy
    • Contact
Home » Jellagen launches JellaGel™, the first Collagen Type 0 Hydrogel taking on the market leading Extracellular Matrix

Jellagen launches JellaGel™, the first Collagen Type 0 Hydrogel taking on the market leading Extracellular Matrix

January 15, 2021 By Cade Hildreth (CEO)

  • JellaGel™ uses Collagen Type 0 (marine sourced jellyfish) and is non-mammalian.

  • The hydrogel kit is easy to use (with Buffer and Crosslinker).

  • JellaGel™ can be used at room temperature.

Jellagen® Limited, a biotechnology company manufacturing high value Collagen Type 0 derived from jellyfish, announce the launch of their JellaGel™ Hydrogel. 3-dimensaional Hydrogels allow cells to grow and interact with all of their surroundings which makes a huge difference. Cells grown in a 3D model have proven to be more natural, with improved cell viability, morphology, proliferation, and differentiation. These are important features enabling researchers to develop JellaGel as a potential matrix for new drug screening models or in the preparation of human tumor xenografts models as part of cancer drug discovery programs.

JellaGel provides customers with a non-mammalian, natural, biochemically simple, consistent, and easy to use hydrogel that can transform their research. Being biochemically simple means there is no unwanted/undefined growth factors or biological contaminants in JellaGel that could negatively influence the culture of cells, giving researchers more control. One of the greatest features of JellaGel is that it can be used at room temperature meaning there is no need for ice or cold rooms, unlike most hydrogels currently on the market.

Jellagen CEO, Thomas-Paul Descamps commented:

“I am very impressed by the work delivered by the team. It has been a long journey as it is a complex challenge for a small company to create, manufacture and launch a hydrogel based on polymers such as Jellyfish collagen. It is also very ambitious in a conservative market where there has been few innovations in the past. But as a result, there are a lot of improvements which can be brought against the competition. Because of the unique scaffold properties of Jellyfish collagen, ‘the stem collagen’ we never gave up on this challenge and are now very proud to bring to the market such an innovative solution to grow cells.”

Jellagen Founder & CSO, Andrew Mearns Spragg commented:

“Jellyfish represent the evolutionary route of all collagens. This Collagen Type 0 is a chemistry innovation and is a breakthrough biomaterial presenting the market with an important alternative to conventional scaffold sources used in 3D cell culture. Researchers will now benefit from JellaGel’s unique features
derived from this non-mammalian and natural (prion / disease-vector free) collagen material such as its chemically simple composition that fundamentally leads to improved batch to batch consistency of 3D cell culture.”

For more information:
Adam Watts, Digital Marketing Manager, Jellagen
T: +44 (0) 3333 583 299
www.jellagen.co.uk

5 / 5 ( 2 votes )

Filed Under: Press Releases, Stem Cell News

Related

About Cade Hildreth (CEO)

Cade Hildreth is the Founder of BioInformant.com, the world's largest publisher of stem cell industry news. Cade is a media expert on stem cells, recently interviewed by the Wall Street Journal, Los Angeles Business Journal, Xconomy, and Vogue Magazine. 

Let’s Get Social

  • Facebook
  • Twitter
  • Instagram
  • Pinterest
  • LinkedIn

Nanocellect

Marathon Products

Menu
  • Blog
  • Stem Cell News
    • Press Releases
  • Stem Cells
    • HSCs
    • iPS Cells
    • MSCs
    • Neural Stem Cells
    • Adipose SCs
  • Exosomes
  • Cell Therapy
    • CAR-T
  • Cord Blood
  • Interviews

Cart

Featured Posts

Alternate Ocean GCBC

Alternate Ocean Offers to Acquire Largest Cord Blood Bank in China (GCBC) for $5/Share

Reelabs, cord blood banking India

ReeLabs: Cord Blood Banking in India (Population 1.4 Billion)

iPSC-derived therapeutics

The Pipeline for iPSC-Derived Cell Therapeutics in 2021

My Tweets

BioInformant's World-Class Clients

  • Submit Press Release
  • Advertise
  • Privacy and Terms

Copyright © 2021 · BIOINFORMANT, Your Global Leader in Stem Cell Market Research

| Email: [email protected] | Phone: 703-859-7617 |

800 Corporate Drive, Suite 301, Stafford, VA 22554, United States

Disclaimer: All statements made on this website are NOT expressed as medical claims or advice. They are not intended to diagnose, treat, cure or prevent any disease or condition. If you have a health condition or concern, consult your physician or health care provider.